{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T17:02:52Z","timestamp":1784480572112,"version":"3.55.0"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"8","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jom-2025-0183_abs_001\">\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Osteoporosis is a prevalent chronic disease associated with fractures, reduced quality of life, and substantial healthcare costs. Randomized controlled trials (RCTs) are essential for developing effective treatments, but when trials are discontinued or unpublished, valuable data are lost. This results in unnecessary costs and exposes thousands of participants to interventions without contributing to clinical\u00a0care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jom-2025-0183_abs_002\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to evaluate the rates and characteristics of discontinuation and nonpublication among US-registered phase 3 and 4 RCTs investigating osteoporosis therapies from 2000 to\u00a02022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jom-2025-0183_abs_003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Phase 3 and 4\u00a0osteoporosis-related RCTs were identified through\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      . Trial completion and publication status were determined utilizing multiple databases and researcher contact. Chi-square and Fisher\u2019s exact tests assessed the associations between trial characteristics and outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jom-2025-0183_abs_004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 303 trials, 29 (9.6\u202f%) were discontinued, and 274 (90.4\u202f%) completed. Among completed trials, 124 (45.3\u202f%) remained unpublished. Discontinuation was significantly more common in nonindustry-funded and single-center trials (p&lt;0.01, p=0.04). Nonpublication was more frequent among industry-funded and internationally recruited trials (p&lt;0.01, p=0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jom-2025-0183_abs_005\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nearly half of osteoporosis RCTs were either discontinued or unpublished, representing a substantial loss of clinical data, financial inefficiency, and ethical concerns. These findings mirror patterns observed in other therapeutic areas, underscoring systemic challenges in clinical research transparency. Strengthening feasibility assessments, enforcing reporting mandates, and addressing structural barriers to trial completion and publication are essential to safeguard research integrity and ensure that patient contributions meaningfully inform medical knowledge.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jom-2025-0183","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:57:36Z","timestamp":1765299456000},"page":"353-360","source":"Crossref","is-referenced-by-count":0,"title":["The impact of discontinuation and non-publishing of osteoporosis clinical trials"],"prefix":"10.1515","volume":"126","author":[{"given":"Daxton","family":"Kennington","sequence":"first","affiliation":[{"name":"Department of Chemistry and Biochemistry, Maeser Chemistry Laboratory , Utah State University , Logan , UT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Simonsen","sequence":"additional","affiliation":[{"name":"College of Medicine, Kansas City University , Joplin , MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Shae","sequence":"additional","affiliation":[{"name":"Assistant Professor of Biostatistics , Center for Population Health and Equity, Kansas City University College of Biosciences, Kansas City University , Kansas City , MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Satterwhite","sequence":"additional","affiliation":[{"name":"Center for Population Health and Equity, Kansas City University , Kansas City , MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"2026071916593272121_j_jom-2025-0183_ref_001","unstructured":"Jager, W. The importance of clinical trials in advancing medical research. Ann Clin Trials Vaccines Res 2023;13:93\u20138."},{"key":"2026071916593272121_j_jom-2025-0183_ref_002","doi-asserted-by":"crossref","unstructured":"De Angelis, C, Drazen, JM, Frizelle, FA, Haug, C, Hoey, J, Horton, R, International Committee of Med, ical Journal Editors, et al.. Clinical trial registration: a statement from the International Committee of Medical Journal. Ann Intern Med 2004;141:477\u20138. https:\/\/doi.org\/10.7326\/0003-4819-141-6-200409210-00109.","DOI":"10.7326\/0003-4819-141-6-200409210-00109"},{"key":"2026071916593272121_j_jom-2025-0183_ref_003","doi-asserted-by":"crossref","unstructured":"Vorland, CJ, Brown, AW, Kilicoglu, H, Ying, X, Mayo-Wilson, E. Publication of results of registered trials with published study protocols, 2011\u20132022. JAMA Netw Open 2024;7:e2350688. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50688.","DOI":"10.1001\/jamanetworkopen.2023.50688"},{"key":"2026071916593272121_j_jom-2025-0183_ref_004","doi-asserted-by":"crossref","unstructured":"Wendelborn, C, Anger, M, Schickhardt, C. Promoting data sharing: the moral obligations of public funding agencies. Sci Eng Ethics 2024;30:35. https:\/\/doi.org\/10.1007\/s11948-024-00491-3.","DOI":"10.1007\/s11948-024-00491-3"},{"key":"2026071916593272121_j_jom-2025-0183_ref_005","doi-asserted-by":"crossref","unstructured":"Ross, MW, Iguchi, MY, Panicker, S. Ethical aspects of data sharing and research participant protections. Am Psychol 2018;73:138\u201345. https:\/\/doi.org\/10.1037\/amp0000240.","DOI":"10.1037\/amp0000240"},{"key":"2026071916593272121_j_jom-2025-0183_ref_006","doi-asserted-by":"crossref","unstructured":"Joy, EA, Briesacher, M, Wiegand, B. Musculoskeletal failure. Am J Lifestyle Med 2024;18:826\u20139. https:\/\/doi.org\/10.1177\/15598276241256878.","DOI":"10.1177\/15598276241256878"},{"key":"2026071916593272121_j_jom-2025-0183_ref_007","doi-asserted-by":"crossref","unstructured":"Lewiecki, EM, Ortendahl, JD, Vanderpuye-Orgle, J, Grauer, A, Arellano, J, Lemay, J, et al.. Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United\u00a0States. JBMR Plus 2019;3:e10192. https:\/\/doi.org\/10.1002\/jbm4.10192.","DOI":"10.1002\/jbm4.10192"},{"key":"2026071916593272121_j_jom-2025-0183_ref_008","unstructured":"Department of Health and Human Services. The final rule. https:\/\/www.cms.gov\/OpenPayments\/Downloads\/Affordable-Care-Act-Section-6002-Final-Rule.pdf [Accessed 9 Nov 2024]."},{"key":"2026071916593272121_j_jom-2025-0183_ref_009","unstructured":"ClinicalTrials.gov. Checklist for evaluating whether a clinical trial or study is an Applicable Clinical Trial (ACT) Under 42 CFR 11.22(b) for clinical trials initiated on or after January 18, 2017; 2018. https:\/\/cdn.clinicaltrials.gov\/documents\/ACT_Checklist.pdf."},{"key":"2026071916593272121_j_jom-2025-0183_ref_010","doi-asserted-by":"crossref","unstructured":"Huang, H, Chen, Z, Zhu, M, Deng, X, Yu, L, Weng, H, et al.. Discontinuation and nonpublication of nasopharyngeal carcinoma clinical trials. Oral Oncol 2024;148:106656. https:\/\/doi.org\/10.1016\/j.oraloncology.2023.106656.","DOI":"10.1016\/j.oraloncology.2023.106656"},{"key":"2026071916593272121_j_jom-2025-0183_ref_011","doi-asserted-by":"crossref","unstructured":"Roddick, AJ, Chan, FTS, Stefaniak, JD, Zheng, SL. Discontinuation and non-publication of clinical trials in cardiovascular medicine. Int J Cardiol 2017;244:309\u201315. https:\/\/doi.org\/10.1016\/j.ijcard.2017.06.020.","DOI":"10.1016\/j.ijcard.2017.06.020"},{"key":"2026071916593272121_j_jom-2025-0183_ref_012","unstructured":"Background ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/about-site\/background [Accessed 9 Nov 2024]."},{"key":"2026071916593272121_j_jom-2025-0183_ref_013","doi-asserted-by":"crossref","unstructured":"Mouw, TJ, Hong, SW, Sarwar, S, Fondaw, AE, Walling, AD, Al-Kasspooles, M, et al.. Discontinuation of surgical versus nonsurgical clinical trials: an analysis of 88,498 trials. J\u00a0Surg Res 2018;227:151\u20137. https:\/\/doi.org\/10.1016\/j.jss.2018.02.039.","DOI":"10.1016\/j.jss.2018.02.039"},{"key":"2026071916593272121_j_jom-2025-0183_ref_014","doi-asserted-by":"crossref","unstructured":"Khan, MS, Shahid, I, Asad, N, Greene, SJ, Khan, SU, Doukky, R, et al.. Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. ESC Heart Fail 2021;8:16\u201325. https:\/\/doi.org\/10.1002\/ehf2.13099.","DOI":"10.1002\/ehf2.13099"},{"key":"2026071916593272121_j_jom-2025-0183_ref_015","doi-asserted-by":"crossref","unstructured":"Emanuel, EJ, Wendler, D, Grady, C. What makes clinical research ethical? JAMA 2000;283:2701\u201311. https:\/\/doi.org\/10.1001\/jama.283.20.2701.","DOI":"10.1001\/jama.283.20.2701"},{"key":"2026071916593272121_j_jom-2025-0183_ref_016","doi-asserted-by":"crossref","unstructured":"Dwan, K, Gamble, C, Williamson, PR, Kirkham, JJ, Reporting Bias Group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias\u00a0\u2013\u00a0an updated review. PLoS One 2013;8:e66844. https:\/\/doi.org\/10.1371\/journal.pone.0066844.","DOI":"10.1371\/journal.pone.0066844"},{"key":"2026071916593272121_j_jom-2025-0183_ref_017","doi-asserted-by":"crossref","unstructured":"Dwan, K, Gamble, C, Williamson, PR, Kirkham, JJ, Reporting Bias Group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias\u00a0\u2013\u00a0an updated review. PLoS One 2013;8:e66844. https:\/\/doi.org\/10.1371\/journal.pone.0066844.","DOI":"10.1371\/journal.pone.0066844"},{"key":"2026071916593272121_j_jom-2025-0183_ref_018","doi-asserted-by":"crossref","unstructured":"Kim, E, Yang, J, Park, S, Shin, K. Factors affecting success of new drug clinical trials. Ther Innov Regul Sci 2023;57:737\u201350. https:\/\/doi.org\/10.1007\/s43441-023-00509-1.","DOI":"10.1007\/s43441-023-00509-1"},{"key":"2026071916593272121_j_jom-2025-0183_ref_019","doi-asserted-by":"crossref","unstructured":"Briel, M, Elger, BS, McLennan, S, Schandelmaier, S, von Elm, E, Satalkar, P. Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial stakeholders in Switzerland, Germany, and Canada. Trials 2021;22:844. https:\/\/doi.org\/10.1186\/s13063-021-05818-0.","DOI":"10.1186\/s13063-021-05818-0"},{"key":"2026071916593272121_j_jom-2025-0183_ref_020","doi-asserted-by":"crossref","unstructured":"Kasenda, B, von Elm, E, You, J, Bl\u00fcmle, A, Tomonaga, Y, Saccilotto, R, et al.. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA 2014;311:1045\u201351. https:\/\/doi.org\/10.1001\/jama.2014.1361.","DOI":"10.1001\/jama.2014.1361"},{"key":"2026071916593272121_j_jom-2025-0183_ref_021","doi-asserted-by":"crossref","unstructured":"Briel, M, Olu, KK, von Elm, E, Kasenda, B, Alturki, R, Agarwal, A, et al.. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J\u00a0Clin Epidemiol 2016;80:8\u201315. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.07.016.","DOI":"10.1016\/j.jclinepi.2016.07.016"},{"key":"2026071916593272121_j_jom-2025-0183_ref_022","doi-asserted-by":"crossref","unstructured":"Jones, CW, Handler, L, Crowell, KE, Keil, LG, Weaver, MA, Platts-Mills, TF. Non-publication of large randomized clinical trials: cross sectional analysis. BMJ 2013;347:f6104. https:\/\/doi.org\/10.1136\/bmj.f6104.","DOI":"10.1136\/bmj.f6104"},{"key":"2026071916593272121_j_jom-2025-0183_ref_023","doi-asserted-by":"crossref","unstructured":"Shepard, S, Anderson, JM, Heigle, B, Thompson, JC, Detweiler, B, Hartwell, M, et al.. Rates of discontinuation and non-publication of upper and lower extremity fracture clinical trials. J\u00a0Orthop Surg Res 2023;18:256. https:\/\/doi.org\/10.1186\/s13018-023-03698-5.","DOI":"10.1186\/s13018-023-03698-5"},{"key":"2026071916593272121_j_jom-2025-0183_ref_024","doi-asserted-by":"crossref","unstructured":"Anderson, ML, Peterson, ED, Bierer, BE. Compliance with results reporting at ClinicalTrials.gov. N\u00a0Engl J Med 2015;372:2370\u20131. https:\/\/doi.org\/10.1056\/NEJMc1504513.","DOI":"10.1056\/NEJMc1504513"},{"key":"2026071916593272121_j_jom-2025-0183_ref_025","doi-asserted-by":"crossref","unstructured":"Anderson, ML, Chiswell, K, Peterson, ED, Tasneem, A, Topping, J, Califf, RM. Compliance with results reporting at ClinicalTrials.gov. N\u00a0Engl J Med 2015;372:1031\u20139. https:\/\/doi.org\/10.1056\/NEJMsa1409364.","DOI":"10.1056\/NEJMsa1409364"},{"key":"2026071916593272121_j_jom-2025-0183_ref_026","doi-asserted-by":"crossref","unstructured":"Lundh, A, Sismondo, S, Lexchin, J, Busuioc, OA, Bero, L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12:MR000033. https:\/\/doi.org\/10.1002\/14651858.MR000033.pub2. Update in: Cochrane Database Syst Rev 2017 Feb 16;2:MR000033. doi: 10.1002\/14651858.MR000033.pub3.","DOI":"10.1002\/14651858.MR000033.pub3"},{"key":"2026071916593272121_j_jom-2025-0183_ref_027","doi-asserted-by":"crossref","unstructured":"Brown, CS, Bachmann, GA, Foster, DC, Gabapentin (GABA) Study Group. Challenge of conducting a multicenter clinical trial: experience in commencing a vulvodynia research protocol. J Womens Health (Larchmt) 2013;22:291\u20132. https:\/\/doi.org\/10.1089\/jwh.2013.4281.","DOI":"10.1089\/jwh.2013.4281"},{"key":"2026071916593272121_j_jom-2025-0183_ref_028","doi-asserted-by":"crossref","unstructured":"Alturki, R, Schandelmaier, S, Olu, KK, von Niederh\u00e4usern, B, Agarwal, A, Frei, R, et al.. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications. J\u00a0Clin Epidemiol 2017;81:56\u201363. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.08.011.","DOI":"10.1016\/j.jclinepi.2016.08.011"}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jom-2025-0183\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jom-2025-0183\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T16:59:39Z","timestamp":1784480379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jom-2025-0183\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,12,10]]},"published-print":{"date-parts":[[2026,7,21]]}},"alternative-id":["10.1515\/jom-2025-0183"],"URL":"https:\/\/doi.org\/10.1515\/jom-2025-0183","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]}}}